View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 16, 2019updated 01 Nov 2021 7:21am

Boston Scientific and Edwards Lifesciences to settle patent disputes

Boston Scientific and Edwards Lifesciences have agreed to settle all outstanding patent litigations associated with transcatheter aortic valves, certain mitral valve repair and left atrial appendage closure devices.

Boston Scientific and Edwards Lifesciences have agreed to settle all outstanding patent litigations associated with transcatheter aortic valves, certain mitral valve repair and left atrial appendage closure devices.

As part the agreement, Edwards Lifesciences has made a $180m payment to Boston Scientific. The companies noted that no additional royalties will be owed by either of them.

The medical device companies have been involved in multiple disputes regarding patents of the cardiac devices in the US and Europe.

“As part the agreement, Edwards Lifesciences has made a $180m payment to Boston Scientific. The companies noted that no additional royalties will be owed by either of them.”

Over the past year, Boston Scientific had reported favourable decisions in both regions.

In December last year, the US District Court for the District of Delaware said that Edwards Lifesciences’ Sapien 3 Aortic Valve infringes Boston Scientific’s patent.

The court also concluded that the Boston Scientific LOTUS Aortic Valve System does not infringe Edwards Lifesciences’ Spenser patents in the country.

Boston Scientific is planning to commercially launch the LOTUS System this year in the US as well as CE-Mark accepting European countries.

Furthermore, the company received similar decisions, claiming the Sapien 3 device infringes Boston Scientific patent, in Germany and the UK in October and March last year, respectively.

Under the latest arrangement, all pending cases between the companies in courts and patent offices will be dismissed. Any existing injunctions will also be lifted.

The companies in a joint statement said: “All pending cases or appeals in courts and patent offices between the two companies will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices, and left atrial appendage closure devices.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU